Darbepoetin alfa + canakinumab for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Mar 2021: Trial registered, NCT04798339
  2. 30 Mar 2021: Trial started, NCT04798339

The trials

NCT04798339: Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

State
Under way
Phase
Phase 1 and Phase 2
People
13 taking part
Started
30 Mar 2021
Primary completion
26 May 2025
Arms
Phase 1b: Dose Level 1, Phase 1b: Dose Level 2, Phase 2: Treatment at Maximum Tolerated Dose
Results
None posted
  1. 15 Mar 2021: Trial registered
  2. 30 Mar 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.